Orphan drugs to be wholly reviewed.

Published: 2001-07-16 07:00:00

Updated: 2001-07-16 07:00:00

The KFDA is going to reshuffle the orphan drug administrative regulation for the purpose of adjusting it more reasonable and eliminating any possible short-cut applications to its nomination.

At present the KFDA is considering to exclude some items out of the total 85 orphan drugs when the dru...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK